DexCom Hit With FDA Warning Letter For Adverse Event Deficiencies
This article was originally published in The Gray Sheet
Executive Summary
The firm says an FDA warning letter it received cites violations based on “recent updates” to FDA’s Medical Device Reporting program made in a draft guidance last year. But FDA emphasizes that it does not take enforcement actions based on how a company implements a guidance document, draft or final.
You may also be interested in...
Is Draft Guidance More Than Meets The Eye? Senators Seek Answers From FDA
Republicans on the Senate HELP Committee say they are concerned that FDA is using draft guidance documents to set substantive policy, which they argue puts companies in a difficult position.
News Briefs: PillCam Colon Clearance; CGM For Pediatrics; SGR Reform Bill
Given Imaging, soon to be part of Covidien, gained clearance for PillCam Colon capsule endoscopy device. FDA approves its first continuous glucose monitoring system for kids. Congress makes progress in the sustainable growth rate formula bill. More news.
The Artificial Pancreas: A Race To The Finish
The first fully functional artificial pancreas for patients with diabetes could be ready for regulatory submission in the next few years. Medtronic has achieved notable success in this area to date, but positive clinical studies have put J&J in a good position as well, and the medical community is watching closely as the major developments in this groundbreaking endeavor continue to move forward.